Home
News
Create
Screeners
Insights
Lactose
102.
00
-2.15
(-2.06%)
Market Cap
₹128.39 Cr
PE Ratio
21.61
Industry
Healthcare
Buy
Sell
Company Performance:
1D
-2.06%
1M
-15.95%
6M
-8.89%
1Y
+1.49%
5Y
+195.22%
View Company Insights
Latest news about Lactose
Lactose board to consider forfeiture of 15,00,000 warrants on June 18
8 days ago
Lactose (India) Ltd will hold a board meeting on June 18, 2026, to forfeit 15,00,000 warrants issued to SG General Dealers LLP due to non-payment. The warrants were issued on a preferential basis, and the forfeiture follows a failure to pay the balance consideration for conversion into equity shares.
Lactose India FY26 Net Profit Rises 17% to ₹606.28 Lakh
May 20, 2026
Lactose (India) Limited Submits Q4 FY26 Securities Dematerialization Certificate to BSE
Apr 14, 2026
Lactose India EGM Approves Vitanosh Merger with Overwhelming Shareholder Support
Mar 31, 2026
Lactose India Adopts New Business Line in Specialized Pharmaceutical Excipients with ₹15 Crore Investment
Jan 30, 2026
More news about Lactose
16
Jan 26
SST Private Family Trust Completes SEBI Disclosure for Lactose India Stake Transfer
SST Private Family Trust filed comprehensive regulatory disclosure with SEBI on January 14, 2026, regarding its completed acquisition of 4.57% stake in Lactose (India) Limited. The inter-se transfer from Madhusha Lifecare Private Limited was executed at ₹61.00 per share on December 17, 2025, with all regulatory compliance requirements met within prescribed timelines.
24
Oct 25
Lactose India Limited's Credit Rating Reaffirmed at CRISIL BBB-/Stable
CRISIL Ratings Limited has reaffirmed the BBB-/Stable credit rating for Lactose India Limited's long-term bank facilities totaling Rs. 60.00 crore from Bank of Baroda. The rating covers cash credit, proposed working capital facilities, and term loans. The rating indicates moderate safety for timely servicing of financial obligations with moderate credit risk. The rating is valid until March 31, 2026.
23
Aug 25
Lactose (India) Limited Secures BSE Approval for Vitanosh Ingredients Merger
Lactose (India) Limited has received a no-objection observation letter from BSE Limited for its proposed merger with Vitanosh Ingredients Private Limited. The BSE issued the letter on August 22, 2025, containing no adverse observations. The merger scheme, approved by the Board of Directors in October 2024, falls under Sections 230 to 232 of the Companies Act, 2013. While this is a significant step, the merger still requires additional regulatory and statutory approvals. The company has made the BSE observation letter available on its website for transparency.
Lactose
102.
00
-
2.
15
(-
2.
06
%)
1 Year Returns:
+1.49%
Industry Peers
Sun Pharmaceutical
1,868.00
(+
0.
27
%)
Divis Laboratories
6,747.00
(-
0.
60
%)
Torrent Pharmaceuticals
4,514.10
(+
1.
28
%)
Cipla
1,433.10
(+
1.
23
%)
Zydus Life Science
1,112.20
(+
2.
46
%)
Dr Reddys Laboratories
1,301.30
(+
0.
82
%)
Lupin
2,357.80
(+
0.
76
%)
Mankind Pharma
2,528.60
(-
0.
38
%)
Aurobindo Pharma
1,534.20
(+
2.
84
%)
Laurus Labs
1,481.00
(+
3.
14
%)
Get More Market Insights with
Heatmap
FII/DII
Company Filings
MF Holdings
Bulk/ Block Deals
Stock Rental via SLBM
Signals
MTF Insights
F&O Ban - MWPL
Top Deliveries
Market Valuation
IPO
Cyclical Trend
Events Calendar